Cargando…

High-dose single-fraction IMRT versus fractionated external beam radiotherapy for patients with spinal bone metastases: study protocol for a randomized controlled trial

BACKGROUND: Stereotactic body radiation therapy (SBRT)using intensity-modulated radiotherapy (IMRT) can be a safe modality for treating spinal bone metastasis with enhanced targeting accuracy and an effective method for achieving good tumor control and a rigorous pain response. METHODS/DESIGN: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Rief, Harald, Katayama, Sonja, Bruckner, Thomas, Rieken, Stefan, Bostel, Tilman, Förster, Robert, Schlampp, Ingmar, Wolf, Robert, Debus, Jürgen, Sterzing, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465731/
https://www.ncbi.nlm.nih.gov/pubmed/26054533
http://dx.doi.org/10.1186/s13063-015-0761-7
Descripción
Sumario:BACKGROUND: Stereotactic body radiation therapy (SBRT)using intensity-modulated radiotherapy (IMRT) can be a safe modality for treating spinal bone metastasis with enhanced targeting accuracy and an effective method for achieving good tumor control and a rigorous pain response. METHODS/DESIGN: This is a single-center, prospective randomized controlled trial to evaluate pain relief after RT and consists of two treatment groups with 30 patients in each group. One group will receive single-fraction intensity-modulated RT with 1×24 Gy, and the other will receive fractionated RT with 10×3 Gy. The target parameters will be measured at baseline and at 3 and 6 months after RT. DISCUSSION: The aim of this study is to evaluate pain relief after RT in patients with spinal bone metastases by means of two different techniques: stereotactic body radiation therapy and fractionated RT. The primary endpoint is pain relief at the 3-month time-point after RT. Secondly, quality of life, fatigue, overall and bone survival, and local control will be assessed. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02358720 (June 2, 2015).